PMDA Blue Letter: Serious Liver Injury Safety Alert for Tabuneos Capsules 10 mg
タブネオスカプセル10mgによる重篤な肝機能障害についての安全性速報（ブルーレター）を掲載しました
Published: 2026-05-21 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Medium · First detected by this dashboard: 2026-08-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
The Pharmaceuticals and Medical Devices Agency (PMDA) posted on its safety updates page a Safety Alert (known as a 'Blue Letter') concerning serious hepatic (liver) dysfunction associated with Tabuneos Capsules 10 mg. The item was published on 2026-05-21; the metadata provides only the Japanese title and a generic note that this is a new safety-information posting.
Business Impact
Pharmaceutical companies, healthcare providers, and pharmacies handling this product may need to consider whether the alert affects prescribing information, pharmacovigilance activities, or patient communications. The actual scope and any required measures cannot be determined from the metadata provided.
Recommended Action
Review the official Japanese PMDA notice at the source URL to confirm the specific safety information, affected patients, and any requested measures.